Oral GLP-1 approved

The Food and Drug Administration has approved Wegovy in pill form, giving U.S. patients the first oral glucagon-like peptide-1 drug for chronic weight management. (fda.gov) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and slows how fast food leaves the stomach. The new approval covers adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside diet and physical activity. (fda.gov) Novo Nordisk said the once-daily pill was approved on December 22, 2025, under the Wegovy brand and prepared for a U.S. launch in early January 2026. The company already sells oral semaglutide for type 2 diabetes under the Rybelsus brand. (novo-pi.com 1) (novo-pi.com 2) In Novo Nordisk’s phase 3 OASIS 4 trial, adults without diabetes who took oral semaglutide for 64 weeks lost more weight on average than people on placebo. Company materials said 307 adults were enrolled, and 76% of people on the pill lost at least 5% of body weight, versus 31% on placebo. (novo-pi.com) (ajmc.com) The approval adds a non-injection option in a market that has been dominated by weekly shots such as Wegovy and Zepbound. It also comes as obesity treatment is moving into primary care, telehealth, and pharmacy-backed programs that are trying to make prescribing and follow-up easier. (fda.gov) (cnbc.com) Coverage is still uneven. KFF reported that on April 21, 2026, the Centers for Medicare & Medicaid Services said the BALANCE model would not be implemented in Medicare Part D in 2027 as originally planned, and that the GLP-1 Bridge program would instead be extended through 2027. (kff.org) The Centers for Medicare & Medicaid Services still says BALANCE is meant to expand access to selected glucagon-like peptide-1 drugs and lifestyle interventions for people in Medicare and Medicaid. But Axios and STAT reported that the Medicare piece stalled after insurers raised concerns about participating. (cms.gov) (axios.com) (statnews.com) Private-sector access is expanding at the same time. Amazon One Medical launched a GLP-1 program on April 21 that combines obesity care visits with Amazon Pharmacy, and CNBC reported prices could start as low as $25 a month for the drugs with insurance. (news5cleveland.com) (cnbc.com) For patients, the new pill changes the form of the treatment, not the larger fight over who pays. The Food and Drug Administration has cleared the first oral option, but Medicare policy and employer or commercial coverage will still decide how widely it is used. (fda.gov) (kff.org)